CO5540299A2 - Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas - Google Patents
Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadasInfo
- Publication number
- CO5540299A2 CO5540299A2 CO03106071A CO03106071A CO5540299A2 CO 5540299 A2 CO5540299 A2 CO 5540299A2 CO 03106071 A CO03106071 A CO 03106071A CO 03106071 A CO03106071 A CO 03106071A CO 5540299 A2 CO5540299 A2 CO 5540299A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- methyl
- optionally substituted
- tiazol
- oxazol
- Prior art date
Links
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0113233.1A GB0113233D0 (en) | 2001-05-31 | 2001-05-31 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5540299A2 true CO5540299A2 (es) | 2005-07-29 |
Family
ID=9915638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO03106071A CO5540299A2 (es) | 2001-05-31 | 2003-12-02 | Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6867225B2 (enExample) |
| EP (1) | EP1392665B1 (enExample) |
| JP (1) | JP2004532266A (enExample) |
| KR (1) | KR20040007633A (enExample) |
| CN (1) | CN1529698A (enExample) |
| AT (1) | ATE377007T1 (enExample) |
| AU (1) | AU2002312954B2 (enExample) |
| BR (1) | BR0210077A (enExample) |
| CA (1) | CA2448103A1 (enExample) |
| CO (1) | CO5540299A2 (enExample) |
| CZ (1) | CZ20033250A3 (enExample) |
| DE (1) | DE60223245T2 (enExample) |
| ES (1) | ES2295352T3 (enExample) |
| GB (1) | GB0113233D0 (enExample) |
| HU (1) | HUP0400056A2 (enExample) |
| IL (1) | IL158818A0 (enExample) |
| MX (1) | MXPA03010584A (enExample) |
| NO (1) | NO20035316D0 (enExample) |
| PL (1) | PL367215A1 (enExample) |
| WO (1) | WO2002096894A1 (enExample) |
| ZA (1) | ZA200308864B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| GB0113231D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
| GB0113232D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical process |
| AU2003264018A1 (en) * | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| CA2497901A1 (en) | 2002-09-06 | 2004-03-18 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| GB0314370D0 (en) * | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
| WO2005060958A1 (en) * | 2003-12-19 | 2005-07-07 | Kalypsys, Inc. | (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes |
| FR2866339B1 (fr) * | 2004-02-18 | 2006-05-05 | Pf Medicament | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| FR2882359A1 (fr) * | 2005-02-24 | 2006-08-25 | Negma Lerads Soc Par Actions S | Derives activateurs de ppar, procede de preparation et application en therapeutique |
| FR2882750B1 (fr) | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| WO2007126043A1 (ja) * | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | チアゾール環を含むカルボン酸誘導体の医薬用途 |
| FR2901792A1 (fr) * | 2006-06-06 | 2007-12-07 | Negma Lerads Soc Par Actions S | DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE |
| WO2008035359A2 (en) * | 2006-06-12 | 2008-03-27 | Cadila Healthcare Limited | Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010064633A1 (ja) | 2008-12-01 | 2010-06-10 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体およびその医薬用途 |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
| US6207422B1 (en) * | 1998-04-17 | 2001-03-27 | The Metrohealth System | Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the same |
| WO2000018903A2 (en) * | 1998-09-29 | 2000-04-06 | The Johns Hopkins University | Inducible genetic suppression of cellular excitability |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| JP2004517100A (ja) * | 2000-12-20 | 2004-06-10 | グラクソ グループ リミテッド | ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール |
-
2001
- 2001-05-31 GB GBGB0113233.1A patent/GB0113233D0/en not_active Ceased
-
2002
- 2002-05-29 US US10/478,259 patent/US6867225B2/en not_active Expired - Fee Related
- 2002-05-29 CN CNA028110803A patent/CN1529698A/zh active Pending
- 2002-05-29 KR KR10-2003-7015688A patent/KR20040007633A/ko not_active Withdrawn
- 2002-05-29 AT AT02738123T patent/ATE377007T1/de not_active IP Right Cessation
- 2002-05-29 WO PCT/EP2002/005885 patent/WO2002096894A1/en not_active Ceased
- 2002-05-29 BR BR0210077-0A patent/BR0210077A/pt not_active IP Right Cessation
- 2002-05-29 AU AU2002312954A patent/AU2002312954B2/en not_active Ceased
- 2002-05-29 ES ES02738123T patent/ES2295352T3/es not_active Expired - Lifetime
- 2002-05-29 MX MXPA03010584A patent/MXPA03010584A/es unknown
- 2002-05-29 IL IL15881802A patent/IL158818A0/xx unknown
- 2002-05-29 EP EP02738123A patent/EP1392665B1/en not_active Expired - Lifetime
- 2002-05-29 JP JP2003500073A patent/JP2004532266A/ja active Pending
- 2002-05-29 HU HU0400056A patent/HUP0400056A2/hu unknown
- 2002-05-29 PL PL02367215A patent/PL367215A1/xx not_active Application Discontinuation
- 2002-05-29 CA CA002448103A patent/CA2448103A1/en not_active Abandoned
- 2002-05-29 CZ CZ20033250A patent/CZ20033250A3/cs unknown
- 2002-05-29 DE DE60223245T patent/DE60223245T2/de not_active Expired - Fee Related
-
2003
- 2003-11-13 ZA ZA200308864A patent/ZA200308864B/en unknown
- 2003-11-28 NO NO20035316A patent/NO20035316D0/no not_active Application Discontinuation
- 2003-12-02 CO CO03106071A patent/CO5540299A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1529698A (zh) | 2004-09-15 |
| EP1392665B1 (en) | 2007-10-31 |
| GB0113233D0 (en) | 2001-07-25 |
| AU2002312954B2 (en) | 2004-12-02 |
| ATE377007T1 (de) | 2007-11-15 |
| BR0210077A (pt) | 2004-06-22 |
| ES2295352T3 (es) | 2008-04-16 |
| NO20035316L (no) | 2003-11-28 |
| NO20035316D0 (no) | 2003-11-28 |
| CA2448103A1 (en) | 2002-12-05 |
| DE60223245D1 (de) | 2007-12-13 |
| IL158818A0 (en) | 2004-05-12 |
| PL367215A1 (en) | 2005-02-21 |
| WO2002096894A1 (en) | 2002-12-05 |
| KR20040007633A (ko) | 2004-01-24 |
| MXPA03010584A (es) | 2004-03-09 |
| EP1392665A1 (en) | 2004-03-03 |
| DE60223245T2 (de) | 2008-08-14 |
| US6867225B2 (en) | 2005-03-15 |
| HUP0400056A2 (hu) | 2004-04-28 |
| ZA200308864B (en) | 2005-02-14 |
| US20040176427A1 (en) | 2004-09-09 |
| CZ20033250A3 (en) | 2004-03-17 |
| JP2004532266A (ja) | 2004-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5540299A2 (es) | Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas | |
| AR046625A1 (es) | Derivados de pirazol y composiciones farmaceuticas. | |
| CO5640132A2 (es) | Piridinonas sustituidas | |
| AR040080A1 (es) | Inhibidores del virus de la hepatitis c | |
| ECSP088431A (es) | Derivados de pirazolo | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| BR0016067A (pt) | Oxazóis substituìdos e derivados tiazóis como ativadores de hppar alfa | |
| AR043210A1 (es) | Compuestos de triazol utiles en terapia | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| CY1107903T1 (el) | Παραγωγα ακυλαμινοθειαζολης και η χρηση τους ως αναστολεις του βητα-αμυλοειδους | |
| CO4810298A1 (es) | Nuevas amidas aromaticas y su procedimiento de preparacion . | |
| SE0101579D0 (sv) | New compounds | |
| SE9703377D0 (sv) | New compounds | |
| JP2005504729A5 (enExample) | ||
| CO5540297A2 (es) | Derivados de oxazol/tiazol activadores del receptor hppar- alfa | |
| AR068695A2 (es) | Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa | |
| EA200101224A1 (ru) | Производные пурина, способ их получения и содержащие их фармацевтические композиции | |
| RU2008110621A (ru) | Производные, имеющие активность агонистов ppar-рецепторов | |
| CO6260092A2 (es) | Compuesto de nicotinamida sustituida y su uso en productos farmaceuticos | |
| AR039122A1 (es) | Derivados de ftalimido como inhibidores de monoamino oxidasa b | |
| ES417638A1 (es) | Procedimiento para preparar oxazoles 2,4,5-trisustituidos. | |
| NO20071230L (no) | Oksazolidinoner inneholdende oksindoler som antibakterielle midler | |
| YU48702B (sh) | Boratni postupak za dobijanje sumpornih derivata imidazola i novi intermedijeri | |
| FI843617A0 (fi) | 4-(2-alkynyloxi-2-hydroxipropyl)- piperazin-1-yl-n-fenyl-acetamidderivat. | |
| AR044672A1 (es) | Compuestos de benzotiazina y benzotiadiazina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |